Eversept Partners LP Sells 70,016 Shares of Evolus, Inc. (NASDAQ:EOLS)

Eversept Partners LP trimmed its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 15.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 383,045 shares of the company's stock after selling 70,016 shares during the period. Eversept Partners LP owned approximately 0.60% of Evolus worth $4,229,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in Evolus by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company's stock worth $13,412,000 after buying an additional 3,969 shares in the last quarter. Schroder Investment Management Group lifted its position in Evolus by 2.5% in the 4th quarter. Schroder Investment Management Group now owns 1,040,440 shares of the company's stock worth $11,330,000 after buying an additional 25,480 shares in the last quarter. Lord Abbett & CO. LLC increased its stake in shares of Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company's stock worth $16,126,000 after purchasing an additional 188,685 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in Evolus by 4.8% in the fourth quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company's stock worth $10,469,000 after purchasing an additional 43,381 shares in the last quarter. Finally, Altium Capital Management LLC increased its position in Evolus by 93.0% during the fourth quarter. Altium Capital Management LLC now owns 685,000 shares of the company's stock worth $7,562,000 after buying an additional 330,000 shares during the last quarter. Institutional investors own 90.69% of the company's stock.

Insider Activity at Evolus

In related news, insider David Moatazedi sold 6,251 shares of the company's stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $12.40, for a total value of $77,512.40. Following the sale, the insider now owns 508,619 shares of the company's stock, valued at $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Rui Avelar sold 27,904 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the transaction, the insider now owns 362,467 shares of the company's stock, valued at approximately $4,806,312.42. This represents a 7.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 60,575 shares of company stock worth $794,369 in the last ninety days. 6.10% of the stock is currently owned by insiders.

Evolus Stock Performance

Shares of EOLS stock traded up $0.10 during trading hours on Friday, reaching $11.65. 800,262 shares of the company's stock were exchanged, compared to its average volume of 668,009. Evolus, Inc. has a fifty-two week low of $8.67 and a fifty-two week high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The stock has a market capitalization of $740.79 million, a P/E ratio of -12.80 and a beta of 0.97. The business has a fifty day moving average price of $12.25 and a 200-day moving average price of $12.95.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on EOLS shares. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. BTIG Research assumed coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target on the stock. Barclays boosted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, April 9th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $23.75.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.